Anti-Human CGRP Recombinant Antibody(Eptinezumab)
-
产品编号
YR1428
-
别名
科研级 Eptinezumab ( 依普奈珠单抗 ), Anti-CGRP Recombinant Antibody, Research Grade Eptinezumab
-
规格
- 1mg
- 5mg
| Catalog Number | YR1428 |
| Alias | 科研级 Eptinezumab ( 依普奈珠单抗 ), Anti-CGRP Recombinant Antibody, Research Grade Eptinezumab |
| Size | 1mg, 5mg |
| Molecular Name | Eptinezumab |
| CAS Number | 1644539-04-7 |
| Target | CGRP[Homo sapiens] |
| Antibody Isotype | IgG1 Kappa |
| Clonity | Monoclonal |
| Concentration | 1mg/ml |
| Purity | >95% as determined by SDS-PAGE |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Formulation | PBS, pH7.5 |
| Shipping Condition | Shipped on ice packs. |
| Background | Eptinezumab, sold under the brand name Vyepti, is a medication for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion every three months. Eptinezumab-jjmr was approved for use in the United States in February 2020. |
| Application | ELISA, IHC, IF, IP, FCM, Inhib |
| Remarks | This product is for research use only. |
0